Intranasal administration of convalescent plasma protects against SARS-CoV-2 infection in hamsters
Description
BACKGROUND: Convalescent plasma (CP) transfusion is an early option for treating infections with pandemic potential, often preceding vaccine or antiviral drug rollout. Heterogenous findings from randomized clinical trials on transfusion of COVID-19